☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
IO Biotech
PharmaShots Interview: In Conversation with IO Biotech’s CEO, Mai-Britt Zocca, Where she Shares Insights on the New Data from Met...
June 28, 2022
IO Biotech Reports First Patient Dosing of IO102-IO103 + Keytruda (pembrolizumab) in the P-III (IOB-013 / KN-D18) Trial as 1L Trea...
May 19, 2022
Insights+: Breakthrough Therapy Designation by the US FDA in 2020
March 11, 2021
IO Biotech's IO102 + IO103 Receive the US FDA's Breakthrough Therapy Designation for Unresectable/ Metastatic Melanoma
December 15, 2020
Load more...
Back to Home